Introduction {#section6-0269881118780010}
============

Almost 4% of all global deaths can be attributed to harmful alcohol consumption ([@bibr53-0269881118780010]). In the European Union, prevalence rates for problematic alcohol use are particularly high, with 3.5% of all drinkers meeting criteria for alcohol dependence (AD; [@bibr54-0269881118780010]). However, less than 10% of all people with AD receive treatment ([@bibr4-0269881118780010]), and for people who do receive treatment, relapse rates typically exceed 50% after 1 year and reach 70% after 3 years ([@bibr21-0269881118780010]). Baclofen, mainly used for the treatment of spasticity, is a new promising drug for the treatment of AD ([@bibr15-0269881118780010]). In first clinical studies with low dosages of baclofen (30 mg/day), a reduction of craving and alcohol intake was demonstrated ([@bibr2-0269881118780010], [@bibr3-0269881118780010]), although one study reported null findings ([@bibr34-0269881118780010]). Furthermore, two case studies ([@bibr5-0269881118780010]; [@bibr14-0269881118780010]) and a small randomized controlled trial (RCT; [@bibr49-0269881118780010]) examined high dosages of baclofen (up to 270 mg/day) and confirmed a potential beneficial effect of baclofen in the treatment of AD. In a recent RCT ([@bibr10-0269881118780010]), we did not replicate the finding of [@bibr49-0269881118780010], likely related to one or more of three important differences between the studies: patients received medication as add-on to psychosocial therapy (not in [@bibr49-0269881118780010]) leaving less room for improvement, patients had somewhat lower drinking levels and the maximum dosage of baclofen reached in our study was lower (up to 150 mg). In 2014, a temporary recommendation (RTU) for use of baclofen was proclaimed in France, where baclofen is now frequently used as off-label treatment for AD with 200,000 patients initiating baclofen treatment for AD between 2007 and 2013 ([@bibr15-0269881118780010]).

Baclofen acts on the GABA system and is thought to exert its dampening effects on drinking outcomes through the indirect inhibition of dopamine release in the mesocorticolimbic reward pathway ([@bibr18-0269881118780010]). Although this pharmacological mechanism has been established, its precise (neuro-) psychological mechanisms of action are still debated. First, it has been argued that baclofen causes a suppression of alcohol craving ([@bibr1-0269881118780010]; [@bibr18-0269881118780010]; [@bibr47-0269881118780010]). Second, baclofen might act as a partial substitution treatment due to its ethanol-like sedation effects ([@bibr16-0269881118780010]; [@bibr57-0269881118780010]). A third possible mechanism includes a role for anxiety reduction, due to the important role of GABA neurotransmission in anxiety ([@bibr20-0269881118780010]; [@bibr48-0269881118780010]). In line with this, baclofen has been shown to be effective in reducing anxiety in anxiety disorders ([@bibr13-0269881118780010]; [@bibr24-0269881118780010]) and comorbid affective disorders in AD patients ([@bibr43-0269881118780010]). Furthermore, studies examining the efficacy of baclofen for the treatment of AD found indications for a reduction of anxiety levels ([@bibr2-0269881118780010]; [@bibr33-0269881118780010]; [@bibr34-0269881118780010]), although results on anxiolytic effects in AD patients have been inconsistent ([@bibr10-0269881118780010]; [@bibr49-0269881118780010]).

Implicit cognitive motivational processes {#section7-0269881118780010}
-----------------------------------------

With prolonged alcohol and drug use, the motivational system becomes more sensitive to drug cues, and automatically activated motivational processes gain importance ([@bibr56-0269881118780010]). Drug cues may then relatively automatically capture attention (i.e. attentional bias), trigger approach tendencies (i.e. approach bias) or activate implicit affective drug-related memory associations, collectively called implicit cognitive motivational biases (see for a review [@bibr66-0269881118780010]).

For alcohol cues, these cognitive biases are well studied. Studies show that heavy social drinkers compared to occasional social drinkers have an attentional bias towards alcohol-related stimuli ([@bibr31-0269881118780010]; [@bibr68-0269881118780010]), and an attentional bias for alcohol in AD in-patients has also been found ([@bibr50-0269881118780010]). However, findings have not been consistent and an important moderator could be presentation time, with some evidence for an attentional bias for alcohol at short presentation times, and no bias or even an avoidance bias at longer presentation times, a so-called vigilance-avoidance pattern ([@bibr29-0269881118780010]; [@bibr42-0269881118780010]; [@bibr50-0269881118780010]).

Concerning alcohol approach tendencies, studies indicate that heavy drinkers have stronger approach tendencies for alcohol-related stimuli compared to light drinkers ([@bibr76-0269881118780010]), and indications for an approach bias for alcohol have been found in patients with AD ([@bibr73-0269881118780010]). However, findings have not always been consistent and appear to depend on details of the task employed ([@bibr9-0269881118780010]; [@bibr32-0269881118780010]; [@bibr65-0269881118780010]; [@bibr75-0269881118780010]).

Finally, implicit affective memory associations are often assessed with the Implicit Association Task (IAT; [@bibr36-0269881118780010]), and studies show that heavy drinkers have negative and arousal associations with alcohol ([@bibr39-0269881118780010]; [@bibr77-0269881118780010]). Similar results have been found in a clinical sample of patients with AD ([@bibr22-0269881118780010]). Although the task has been used in many varieties in non-dependent drinkers (see for a meta-analysis [@bibr58-0269881118780010]), relatively few studies have reported alcohol associations in AD patients and how they are influenced by treatment (see [@bibr23-0269881118780010] and [@bibr73-0269881118780010] for an exception). Given the hypothesized relevance of anxiety in the effects of baclofen, we here focused on memory associations between alcohol and relaxation.

It has been shown that cognitive biases are positively correlated with craving and future drug use ([@bibr19-0269881118780010]; [@bibr26-0269881118780010]; [@bibr40-0269881118780010]; but see [@bibr17-0269881118780010] for a critical review). Furthermore, since negative emotions may cause alcohol craving and consumption in patients with AD ([@bibr8-0269881118780010]) due to the tension-reducing effect of alcohol, it is suggested that negative emotions can strengthen alcohol-related cognitive biases ([@bibr27-0269881118780010]; [@bibr28-0269881118780010]; [@bibr35-0269881118780010]; [@bibr46-0269881118780010]; [@bibr59-0269881118780010]; [@bibr67-0269881118780010]). Furthermore, studies have found that re-training maladaptive cognitive biases, when added to regular therapy, can lead to a reduction of alcohol use and relapse rates (see for a review [@bibr74-0269881118780010]). These training studies illustrate the possibility to influence drinking behaviour by changing alcohol-related cognitive biases, and the question arises whether this could also be part of the working mechanism of a pharmacological agent used for the treatment of AD, such as baclofen. One indication therefore comes from a recent functional magnetic resonance imaging (fMRI) study, which showed that baclofen could inhibit drug cue-induced motivational processing with subliminal cues in cocaine-dependent patients ([@bibr78-0269881118780010]). We wanted to extend this finding to behavioural measures assessed in patients with AD.

Therefore, the present study examined the effect of baclofen on cognitive biases. The aims of the current study were twofold: First, it was examined whether baclofen had an effect on alcohol-related cognitive biases. Second, since baclofen has been found to reduce anxiety, we further investigated the role of anxiety herein. This study was part of an RCT, in which alcohol-dependent patients received either a low or a high dosage of baclofen, or placebo ([@bibr10-0269881118780010]). Alcohol-related cognitive biases were assessed at baseline and after 4 weeks. More specifically, attentional bias at 500 ms and 1500 ms (for vigilance and avoidance, respectively), approach bias for alcohol and alcohol associations with relaxation were examined. Furthermore, trait anxiety levels were measured at baseline. In order to strengthen cognitive biases and account for the anxiolytic effect of baclofen, we induced negative mood prior to the assessment of the tasks.

We hypothesized that: (1) baclofen, compared to placebo, would weaken cognitive biases for alcohol. In addition, as cognitive biases following a negative mood induction were expected to be stronger for patients with higher levels of trait anxiety, we hypothesized that (2) the effect of baclofen on cognitive biases would be moderated by baseline trait anxiety: a stronger reduction of cognitive biases through baclofen in patients with higher levels of trait anxiety. The goal of the present study was to improve our understanding of the working mechanism of baclofen in order to gain knowledge on how its potential beneficial effect in the treatment of AD can be explained.

Materials and methods {#section8-0269881118780010}
=====================

Participants {#section9-0269881118780010}
------------

The study was part of an RCT on the efficacy of high-dose baclofen for the treatment of AD (Netherlands Trial Register, no. 3681; [@bibr10-0269881118780010]). In the original trial, 151 patients with AD participated. Participants were recruited from two inpatient treatment centres and three outpatient treatment centres. Fifty-eight patients were randomly assigned to high-dose baclofen (up to 150 mg), 31 to low-dose baclofen (30 mg) and 62 to placebo. Since the inclusion of patients fell behind schedule, the inclusion of patients in the low-dose group was stopped halfway in order to ensure a valid comparison between the two extreme groups (see [@bibr10-0269881118780010]). From the 151 patients, the 143 patients who completed the computer tasks at baseline were included in the present study (high-dose baclofen: 54; low-dose baclofen: 29; placebo: 60). For the aim of the present study, the high-dose and the low-dose baclofen groups were merged. This resulted in a (high- and low-dose) baclofen group (*N*= 83), with participants taking between 30 and 110 mg/day baclofen and a placebo group (*N*=60); see [Table 1](#table1-0269881118780010){ref-type="table"} for the distribution of baclofen dosages within the baclofen group at t2. The study was approved by the ethics committee of the Academic Medical Center in Amsterdam.

###### 

Baclofen dosage for the baclofen group at t2.

![](10.1177_0269881118780010-table1)

  *N*   Baclofen dosage (mg/day)
  ----- --------------------------
  20    30
  1     40
  3     50
  2     60
  9     80
  18    110

Inclusion and exclusion criteria {#section10-0269881118780010}
--------------------------------

Inclusion and exclusion criteria from the original trial were met. Inclusion criteria were: (a) between 18 and 70 years; (b) DSM-IV AD-diagnosis; (c) \<0.5% breath alcohol concentration at the screening visit; (d) an average alcohol consumption of ≥ 14 units (1 unit contained 10 g of ethanol) for women and ≥ 21 units for men per week over a consecutive 30-day period in the 90-day period before the start of the study and at least 2 heavy drinking days (women ≥ 5 units; men ≥ 6 units) in the past 90 days; (e) ≥ 96 h and ≥ 21 days abstinence prior to the initiation of the study medication; (f) Dutch language skills; and (g) provision of a contact person in the event of loss of contact. Exclusion criteria were: (a) current severe axis I disorder (other than depression, anxiety and bipolar disorder); (b) a primary diagnosis of substance dependence other than AD (excluding nicotine dependence); (c) severe physical illness (e.g. Parkinson's disease, gastric ulcer, duodenal ulcer, cerebrovascular disease, respiratory insufficiency, hepatic or renal insufficiency, and epilepsy); (d) medication for hypertension; (e) risk of suicide; (f) cognitive impairment; (g) current or recent (past 3 months) pharmacological treatment for AD (i.e. acamprosate, naltrexone, disulfiram or topiramate); (h) pregnancy or breastfeeding; (i) ≥ 7 days inpatient treatment for substance disorder in the past 30 days; and (j) the use of baclofen in the past 30 days. Informed consent was obtained from all participants.

Medication {#section11-0269881118780010}
----------

The original trial consisted of a 6-week titration phase and a 10-week high-dose phase, where dosage was stabilized. Pills were provided in identical tablets and were taken three times a day. Participants started with 30 mg/day (three times 10 mg) baclofen or placebo, and the dose was increased with 10 mg baclofen for the high-dose group or placebo for the low-dose and the placebo group every other day, resulting in an increase of 30 mg/week and a maximum dosage of 150 mg/day within 6 weeks. In case of prolonged side effects, the dosage was reduced to the previous dosage and increased again. Hence, participants in the high-dose baclofen group could reach a daily dosage of up to 150 mg within 6 weeks depending on tolerance (see [@bibr10-0269881118780010] for a detailed description of the RCT). In the present study, participants could reach a maximal daily dosage of up to 110 mg within 4 weeks.

Questionnaires {#section12-0269881118780010}
--------------

The following patient characteristics were collected: demographic data, severity of alcohol-related problems (Alcohol Use Disorder Identification Test; AUDIT; [@bibr60-0269881118780010]), drinking history (European Addiction Severity Index; EuropASI; [@bibr11-0269881118780010]), alcohol use in the past 30 days (Timeline Follow Back; TLFB; [@bibr63-0269881118780010]) and craving (Obsessive Compulsive Drinking Scale; OCDS; [@bibr6-0269881118780010]). Trait anxiety was measured with the trait version of the State-Trait Anxiety Inventory (STAI trait; [@bibr64-0269881118780010]). Current affective and arousal state was assessed with the Self Assessment Manikin ([@bibr12-0269881118780010]) in order to examine the manipulation of affect. Participants indicated their affective and arousal state on a 9-point scale, with the lowest score indicating unhappy or relaxed and the highest score indicating happy or excited, respectively.

Negative mood induction {#section13-0269881118780010}
-----------------------

Before each measure of cognitive biases, a negative mood induction procedure took place. Negative affect was induced with a personalized stress imagery task based on [@bibr61-0269881118780010]. In this task, participants identified and reported a stressful event that was not related to alcohol. They were asked to concentrate on cognitions, emotions and physiological responses while describing the event.

Measures of cognitive biases {#section14-0269881118780010}
----------------------------

### Dot Probe Task (DPT) {#section15-0269881118780010}

Attentional bias was assessed with the alcohol-DPT ([@bibr31-0269881118780010]). After 10 practice trials, 15 alcohol images paired with 15 soda images were shown in 60 critical trials, and 14 negative images were used for 28 negative filler trials. A trial started with a fixation cross presented for 500 ms. Thereafter the picture pairs were presented at the left and the right side of the screen. For half of the trials presentation time was 500 ms and for the other half 1500 ms, presented in random order. After images disappeared, a small arrow pointing up or down appeared in the location of one of the images, and participants were instructed to respond to it, as quickly and accurately as possible, by pressing a corresponding key (e- or i-key, counterbalanced) to indicate whether it pointed up or down. Probes replaced images with equal frequency, and there was an equal number of trials with each probe type. Images were presented in random order. Incorrect trials were repeated.

### Approach-Avoidance Task (AAT) {#section16-0269881118780010}

Implicit alcohol-related action tendencies were assessed with the alcohol-AAT ([@bibr76-0269881118780010]). Following 20 practice trials, 15 alcohol images, 15 soda images and 15 negative images were shown semi-randomly (at most three similar rotations and image categories in a row) in 120 critical trials and 60 negative filler trials. Each image was presented twice, rotated 3° to the left or to the right ([@bibr19-0269881118780010]). Participants were instructed to push or pull a joystick depending on the rotation direction. Half of the patients pulled images rotated right and pushed images rotated left, the other half did the opposite. Image size increased or decreased by pulling or pushing the joystick mimicking an approach or avoidance action, respectively. Incorrect trials were repeated.

### Brief Implicit Association Test (BIAT) {#section17-0269881118780010}

Implicit alcohol-related memory associations, specifically alcohol-relaxation associations, were assessed with the BIAT ([@bibr59-0269881118780010]). The BIAT is a short version of the IAT and requires participants to focus on just two of the four categories of each block (we used the traditional seven-block structure). Two target categories, alcohol and soda, and two attribute categories, relaxed and negative, were used. For each category three images were individually presented as category exemplars. At the top of the screen the question 'Does this image belong to' appeared subjacent to the target or attribute words and 'Yes' and 'No' on the left and right as a reminder of the meanings of the corresponding keys. The BIAT consisted of seven blocks including three practice blocks (1, 2 and 5) and four combination blocks (3, 4 and 6, 7). In the practice blocks (12 trials) only one category (alcohol, soda or relaxed) appeared on the screen, and each category exemplar was presented twice. Combination blocks consisted of 16 practice trials (block 3 and 6; 16 trials) and 24 assessment trials (block 4 and 7; 24 trials) where one target and one attribute category (alcohol and relaxed or soda and relaxed) were presented together. One attribute category (negative) never appeared on the screen as a word. Target and attribute category exemplars were presented alternately. Participants were instructed to categorize exemplars to the category word(s) by pressing a corresponding key. The order of the combination blocks was counterbalanced. Incorrect trials were repeated.

Procedure {#section18-0269881118780010}
---------

Participants were recruited after detoxification. Following the screening, the first test session (t1) was scheduled. After the completion of questionnaires, the first negative mood induction took place and the three tasks were conducted. The mood induction was repeated between the tasks, and negative images were included in the tasks in order to sustain the induced negative affect. Participants rated their affective and arousal state before the first mood induction (baseline measure), after each mood induction (before the task) and after completing each task, resulting in seven mood and arousal ratings. After the first test session, patients were randomized to high-dose baclofen, low-dose baclofen or placebo. After 4 weeks, a second test session (t2) was scheduled in which the procedure of the first test session was repeated and questionnaires and tasks following a negative mood induction were assessed again. Since in-patients stayed in the clinic for the duration of 4 weeks, t2 was scheduled before they left. Outpatients who relapsed before t2 were excluded. Relapse was defined as having a heavy drinking day after a lapse (any intake of alcohol). In the original trial a third test session was conducted after 16 weeks, repeating the procedure of t1 and t2. The results of this third test session are not included in the present study, due to the small number of participants who completed the tasks in the final test session at 16 weeks. Tasks were presented in three different counterbalanced orders with the E-prime 2.0 software (Psychology Software Tools, Pittsburgh, PA). Alcohol images and matched soda images were taken from the Amsterdam Beverage Picture Set ([@bibr52-0269881118780010]), and emotional images were taken from the International Affective Picture System (IAPS; [@bibr44-0269881118780010]).

Data preparation of RT data {#section19-0269881118780010}
---------------------------

Practice trials, negative trials and error trials from the DPT and the AAT were discarded. Attentional bias scores were calculated by subtracting median RTs to probes replacing alcohol images from median RTs replacing soda images, with positive scores reflecting an attentional bias towards alcohol. Attentional bias scores were calculated for the presentation duration of 500 ms and 1500 ms separately. Alcohol approach bias scores were calculated by subtracting median approach RTs from median avoid RTs for alcohol images, with positive scores reflecting faster approach reactions ([@bibr55-0269881118780010]; [@bibr76-0269881118780010]). The strength of alcohol-relaxation associations from the BIAT was determined with the D2SD measure using the scoring algorithm from [@bibr37-0269881118780010]. Outliers were identified using the outlier labelling rule, which is based on multiplying the interquartile range by a factor of 2.2, adding the resulting value to the third quartile and subtracting it from the first quartile, and defining outliers as values outside of these boundaries ([@bibr38-0269881118780010]; [@bibr41-0269881118780010]). At t1, one outlier was identified for the DPT 500 ms and three for the alcohol approach bias. At t2, one outlier was identified for the attentional bias at 1500 ms. For the extreme values 'winsorizing' was applied, meaning that extreme values were replaced with the highest acceptable value ([@bibr70-0269881118780010]). At t1, internal reliability was extremely low for the DPT, with a Cronbach's alpha of 0.01. For the AAT Cronbach's alpha was 0.51 for alcohol images. The BIAT had good internal reliability with a Cronbach's alpha of 0.80.

Results {#section20-0269881118780010}
=======

Participants {#section21-0269881118780010}
------------

From the original sample of 151, 143 participants completed at least one task at t1. A total of 138 participants completed the DPT, 138 the AAT and 138 the BIAT. The difference was caused by technical errors, discontinuation of the tasks due to the impact of the negative images or lack of time. DPT scores of three participants and BIAT scores of five participants were excluded from analysis, because of excessive error rates (\>25%), resulting in an analytical sample of 135 participants for the DPT, 138 for the AAT and 133 for the BIAT. Groups did not differ significantly at baseline in demographic or clinical measures (see [Table 2](#table2-0269881118780010){ref-type="table"}).

###### 

Demographic and clinical characteristics of study participants at baseline.

![](10.1177_0269881118780010-table2)

  -----------------------------------------------------------------------------------------------------------
                                       Total\         Baclofen\      Placebo\       *t*-value or chi-square
                                       (*N* = 143)    (*N* = 83)     (*N* = 60)     
  ------------------------------------ -------------- -------------- -------------- -------------------------
  **Demographics**                                                                  

  Age (years)                          44.7 (9.7)     45.2 (9.9)     44.1 (9.3)     *t* = 0.727

  Men                                  98 (68.5%)     56 (67.5%)     42 (70.0%)     *χ*^2^ = 0.103

  Married                              77 (53.9%)     45 (54.2%)     32 (53.3%)     *χ*^2^ = 0.011

  Employed                             84 (58.7%)     46 (55.4%)     38 (63.3%)     *χ*^2^ = 0.899

  **Alcohol use**                                                                   

  Alcohol (g/day)                      143.1 (85.9)   145.0 (85.9)   140.4 (86.5)   *t* = 0.314

  Duration of alcohol abuse (years)    19.5 (11.5)    19.8 (11.7)    19.1 (11.3)    *t* = 0.330

  Duration of abstinence (days)        11.9 (4.7)     11.9 (4.3)     11.9 (4.4)     *t =* −0.037

  Number of previous detoxifications   1.6 (2.9)      1.3 (2.1)      2.1 (3.7)      *t* = −1.536

  **Questionnaires**                                                                

  AUDIT                                28.5 (5.2)     29.0 (5.6)     27.7 (4.5)     *t* = 1.505

  OCDS                                 29.4 (10.1)    28.9 (10.1)    30.2 (10.2)    *t* = −0.720

  STAI trait                           49.9 (11.2)    51.0 (11.5)    48.4 (10.6)    *t* = 1.364
  -----------------------------------------------------------------------------------------------------------

Data are mean (SD) or *n* (%). AUDIT: Alcohol Use Disorder Identification Test; OCDS: Obsessive Compulsive Drinking Scale; STAI trait: State-Trait Anxiety Inventory-trait version. \**p* \< 0.05.

At t2 (after 4 weeks), 94 participants (53 (low- and high) baclofen group, 41 placebo group) completed at least one task. BIAT scores of five participants were excluded because of error rates above 25%. In the baclofen group, 49 participants completed the DPT, 50 participants completed the AAT and 46 participants the BIAT. In the placebo group, 36 participants completed the DPT, 40 participants completed the AAT and 39 the BIAT.

Preliminary analyses {#section22-0269881118780010}
--------------------

### Mood manipulation {#section23-0269881118780010}

Since valence and arousal scores were not normally distributed, a Wilcoxon Signed Rank Test was used in order to examine the mood manipulation. Baseline valence and arousal scores were compared with each of the valence and arousal scores assessed after the three negative mood inductions. Scores indicated a significant increase of negative mood (all *p*'s \< 0.001) and arousal (all *p*'s \< 0.001) following all negative mood inductions for t1 as well as t2, indicating that the induction of negative mood was successful (see [Table 3](#table3-0269881118780010){ref-type="table"}).

###### 

Valence and arousal scores at t1 and t2.

![](10.1177_0269881118780010-table3)

                                Valence scores                                                      Arousal scores
  ----------------------------- ------------------------------------------------------------------- -------------------------------------------------------------------
  **t1 (*N*=133)**                                                                                  
  Baseline                      6.27 (1.48)                                                         3.50 (1.80)
  After first mood induction    3.14 (2.11)[\*](#table-fn2-0269881118780010){ref-type="table-fn"}   6.38 (2.27)[\*](#table-fn2-0269881118780010){ref-type="table-fn"}
  After second mood induction   3.29 (1.86)[\*](#table-fn2-0269881118780010){ref-type="table-fn"}   5.82 (2.15)[\*](#table-fn2-0269881118780010){ref-type="table-fn"}
  After third mood induction    3.53 (2.10)[\*](#table-fn2-0269881118780010){ref-type="table-fn"}   5.70 (2.22)[\*](#table-fn2-0269881118780010){ref-type="table-fn"}
  **t2 (*N*=94)**                                                                                   
  Baseline                      6.91 (1.46)                                                         2.70 (1.62)
  After first mood induction    3.80 (1.91)[\*](#table-fn2-0269881118780010){ref-type="table-fn"}   5.15 (2.16)[\*](#table-fn2-0269881118780010){ref-type="table-fn"}
  After second mood induction   4.04 (2.02)[\*](#table-fn2-0269881118780010){ref-type="table-fn"}   4.97 (2.32)[\*](#table-fn2-0269881118780010){ref-type="table-fn"}
  After third mood induction    4.09 (1.01)[\*](#table-fn2-0269881118780010){ref-type="table-fn"}   4.87 (2.02)[\*](#table-fn2-0269881118780010){ref-type="table-fn"}

Data are mean (SD). \* *p* \< 0.001.

Higher scores indicate positive mood (valence) and higher arousal levels (arousal).

### Bias scores {#section24-0269881118780010}

One-sample t-tests with a test-value of zero were used in order to test the overall presence of cognitive biases. At t1, participants had a significant attentional bias towards alcohol at 500 ms (*p* = 0.043) and a significant attentional bias away from alcohol at 1500 ms (*p* = 0.037). Furthermore, while participants showed no significant alcohol approach bias (*p* = 0.101), they had significantly strong alcohol-negative (vs. alcohol-relaxation) associations (*p* \< 0.001). At t2, only in the baclofen group attentional bias at 500 ms changed from a significant vigilance (attend alcohol) to a significant avoid alcohol bias (*p* = 0.027), a pattern not seen in the placebo group (*p* = 0.425). No significant alcohol approach tendencies but significant alcohol-negative associations were found in both treatment groups (all *p*'s \< 0.001) (see [Table 4](#table4-0269881118780010){ref-type="table"}).

###### 

Bias scores at baseline (t1) and at t2.

![](10.1177_0269881118780010-table4)

                                    *N*   Mean (SD)       *t*-value
  --------------------------------- ----- --------------- -----------------------------------------------------------------
  Attentional bias 500 ms           135   13.5 (76.7)     2.04[\*](#table-fn4-0269881118780010){ref-type="table-fn"}
  Attentional bias 1500 ms          135   --12.9 (71.1)   --2.11[\*](#table-fn4-0269881118780010){ref-type="table-fn"}
  Approach bias alcohol             138   --10.8 (76.8)   --1.65
  Alcohol-relaxation associations   133   --0.8 (0.7)     --13.37[\*\*](#table-fn4-0269881118780010){ref-type="table-fn"}

Bias scores at baseline. \**p* \< 0.05; \*\**p* \< 0.001.

Note: Positive bias scores indicate an attentional bias towards alcohol, an approach bias towards alcohol and alcohol-relaxation associations.

![](10.1177_0269881118780010-table5)

                                    Baclofen   Placebo                                                                                                 
  --------------------------------- ---------- ---------------- ----------------------------------------------------------------- ---- --------------- -----------------------------------------------------------------
  Attentional bias 500 ms           49         --20.1 (61.1)    --2.28[\*](#table-fn6-0269881118780010){ref-type="table-fn"}      36   10.8 (80.7)     0.81
  Attentional bias 1500 ms          49         0.7 (61.1)       --0.09                                                            36   --13.6 (52.9)   --1.54
  Approach bias alcohol             50         --0.8.0 (79.6)   --0.07                                                            40   4.2 (55.7)      0.48
  Alcohol-relaxation associations   46         --1.1 (0.5)      --14.86[\*\*](#table-fn6-0269881118780010){ref-type="table-fn"}   39   --1.1 (0.5)     --14.19[\*\*](#table-fn6-0269881118780010){ref-type="table-fn"}

Bias scores at t2 in the baclofen and the placebo group. \**p* \< 0.05; \*\**p* \< 0.001.

Note: Positive bias scores indicate an attentional bias towards alcohol, an approach bias towards alcohol and alcohol-relaxation associations.

Main analyses {#section25-0269881118780010}
-------------

### Effects of baclofen on cognitive biases and the role of anxiety {#section26-0269881118780010}

STAIT scores at t2 were 39.3 (SD=11.5) for the baclofen group and 38.5 (SD=10.2) for the placebo group (*p* = 0.701). In order to examine the effect of baclofen on cognitive biases and the potential moderating role of anxiety herein, four ANCOVAs on t2 bias scores were conducted, separately for each bias score (attentional bias at 500 ms, attentional bias at 1500 ms, approach bias for alcohol and alcohol-relaxation associations) with treatment group (baclofen or placebo) as the between-subject factor. In order to control for cognitive bias scores at t1, this variable was added as a covariate ([@bibr71-0269881118780010]). Furthermore, to investigate the role of anxiety, trait anxiety measured at t1 was added as a covariate and the interaction between trait anxiety and treatment group was examined.^[1](#fn1-0269881118780010){ref-type="fn"}^

For the attentional bias scores for alcohol at 500 ms and 1500 ms, neither the main effects nor the interaction between treatment group and trait anxiety were significant (all *p*-values \> 0.264). Further, also for approach bias scores, neither the main effects nor the interaction between group and trait anxiety were significant (all *p*-values \> 0.568). Finally, for alcohol-relaxation associations, no significant main effects nor a significant interaction effect were found (all *p*-values \> 0.494).

Discussion {#section27-0269881118780010}
==========

This study examined the effect of baclofen on cognitive biases in AD and the role of anxiety herein. The most important findings were as follows: consistent with the literature, after negative mood induction, patients showed an attentional bias for alcohol at baseline with the typical vigilance-avoidance pattern -- bias towards alcohol at 500 ms and bias away from alcohol at 1500 ms. However, unexpectedly, patients showed no significant approach bias for alcohol and no alcohol-relaxation associations but strong alcohol-negative associations at baseline. Regarding the main aims of the study, we found indications for a change from an attentional bias towards alcohol at 500 ms at baseline away from alcohol after 4 weeks of baclofen treatment. However, baclofen did not lead to a change in cognitive biases compared with the placebo group, and no evidence for a moderating role of anxiety herein could be found.

For cognitive biases at baseline, the pattern of results was mixed, with findings on attentional biases confirming previous research (a pattern of vigilance-avoidance, [@bibr29-0269881118780010]; [@bibr50-0269881118780010]; [@bibr62-0269881118780010]). No overall approach bias for alcohol was found, which is contrary to an earlier study showing indications for an approach bias in AD patients ([@bibr73-0269881118780010]), but in accordance with another study ([@bibr25-0269881118780010]). It is argued that this could have been caused by individual differences or ambivalence between approach and avoidance associations towards alcohol in patients with AD, in particular in AD patients that are receiving treatment. Finally, patients in the present study showed strong alcohol-negative (vs. alcohol-relaxation) associations, which is in accordance with earlier studies demonstrating negative implicit associations with alcohol and alcohol-arousal associations in heavy drinkers and patients with AD ([@bibr22-0269881118780010]; [@bibr77-0269881118780010]). However, in the present study stronger alcohol-relaxation (vs. alcohol-negative) associations were expected, caused by the induction of negative mood prior to the assessment of implicit alcohol associations ([@bibr46-0269881118780010]; [@bibr51-0269881118780010]).

Concerning the effects of baclofen on cognitive biases, the results did not clearly confirm our hypotheses. Our findings suggest that baclofen does not have an effect on approach bias or on implicit alcohol-relaxation (and/or alcohol-negative) associations. Concerning attentional bias, our sample showed an attentional bias at 500 ms towards alcohol at baseline, which changed into an attentional bias away from alcohol only in the baclofen group after 4 weeks. This inhibitory effect of baclofen on attention to alcohol was further confirmed by a moderate within-group effect size in the baclofen group from baseline to t2 (Cohen's *d* = 0.49) compared with a negligible within-group change in the placebo group (Cohen's *d* = 0.03) and is in accordance with earlier research ([@bibr78-0269881118780010]). However, note that attentional bias did not differ between the groups at t2, which could be due to the high variability within the placebo group at t2 and the very low internal reliability of the DPT (Cronbach's alpha of 0.1). In accordance, the literature suggests that the DPT often suffers from low internal reliability, and possible causes are discussed by [@bibr7-0269881118780010]. Furthermore, it should be taken into consideration that with the (rather) long presentation duration of 500 ms and 1500 ms, maintained attention, rather than initial orienting may have been measured in the present study, especially with the long presentation time of 1500 ms. Therefore, further studies are warranted that examine the effect of baclofen on attentional bias taking these issues into consideration.

We decided to examine associations between alcohol and relaxation, since we expected a reduction of anxiety through baclofen, causing a weakening of these associations. However, all patients showed significant alcohol-negative (vs. alcohol-relaxation) associations throughout the whole study ([@bibr22-0269881118780010]; [@bibr77-0269881118780010]), which seemed not to be affected by baclofen. Since this is the first study examining the effect of baclofen on alcohol-relaxation associations in a clinical sample, more research is needed to draw any conclusions.

Results of the present study do not support the hypothesis of a moderating role of trait anxiety on the influence of baclofen on cognitive biases after the induction of negative mood. Several earlier studies found indications of an anxiolytic effect of baclofen ([@bibr2-0269881118780010]; [@bibr33-0269881118780010]; [@bibr34-0269881118780010]; [@bibr43-0269881118780010]; but see [@bibr49-0269881118780010] and [@bibr10-0269881118780010] for null findings). Based on these findings it was suggested that patients with higher trait anxiety levels would respond better to baclofen. However, similar to our results, other studies also failed to confirm a moderating role of trait anxiety on the effect of baclofen ([@bibr34-0269881118780010]; [@bibr45-0269881118780010]). The present study extends these findings with a null effect of baclofen on cognitive biases after negative mood induction.

Several shortcomings of the present study have to be taken into consideration. First, we included a negative mood induction prior to the tasks in order to study the effect of baclofen on negative affect strengthened cognitive biases. The majority of studies found indications for a strengthening of cognitive biases after the induction of negative mood ([@bibr27-0269881118780010]; [@bibr28-0269881118780010]; [@bibr35-0269881118780010]; [@bibr46-0269881118780010]; [@bibr51-0269881118780010]; [@bibr59-0269881118780010]; [@bibr67-0269881118780010]); however, this was the first study examining the effect of negative mood on cognitive biases in AD patients. Although subjective pre- and post-measures indicate that negative mood increased, the precise effect of the negative mood induction on cognitive biases in the present study is not clear, since no control condition with a neutral or positive mood induction was included (this was done to optimize the power for finding an effect of baclofen on these biases), and cognitive biases were only measured after the induction of negative mood. Therefore, studies examining the effect of baclofen on cognitive biases without any induction of mood, or with the addition of groups undergoing a neutral or positive mood induction, are warranted. Second, cognitive biases are not sufficiently examined in clinical populations, especially in treatment-seeking patients with AD. Studies indicate that patients receiving clinical treatment, contrary to heavy drinkers, show negative attentional bias ([@bibr69-0269881118780010]; [@bibr72-0269881118780010]) or no bias at all ([@bibr9-0269881118780010]). Regarding attentional bias, presentation time of the stimuli is likely to play an important role, with some evidence for a vigilance-avoidance pattern ([@bibr29-0269881118780010]) and more reliable assessment is important, where the tracking of eye-movements is promising ([@bibr28-0269881118780010]). Additionally, the relationship between cognitive biases and treatment outcome is not clear. More research is warranted regarding the assessment of cognitive biases and their relationship to alcohol use and relapse in specific groups of drinkers. Third, the majority of the participants in the present study were in-patients receiving intensive psychosocial treatment. As argued in the recent study of [@bibr10-0269881118780010], baclofen (and other medications) might not have a strong additional effect to psychotherapy, which could also have reduced the likelihood of finding an effect of baclofen on cognitive biases. Furthermore, since patients were treated in a clinic, they might have experienced relatively low levels of craving and anxiety, causing the absence of cognitive biases ([@bibr30-0269881118780010]) and subsequently group differences. Further outpatient treatment studies are warranted. Finally, cognitive biases at t2 are only reassessed in patients who did not relapse. However, since it is possible that baclofen might affect cognitive bias measures differently in relapsing and non-relapsing patients, it would be important to examine cognitive biases in both groups.

The present study is the first study examining the effect of baclofen on cognitive biases in AD. We found no clear evidence for a weakening of cognitive biases through baclofen or a moderating role of anxiety herein. Given the current contradictory findings regarding the efficacy of baclofen, a better understanding of the precise working mechanism and the identification of predictors of treatment success would represent valuable knowledge, in order to prescribe baclofen in a more directed manner.
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Analyses with the original three groups (placebo, low-dose baclofen and high-dose baclofen) yielded similar results.
